65,437 trials
Hormone Receptor Positive Breast Carcinoma · HER2-negative Breast Cancer
Primary: Dose Limiting Toxicities (DLT) — 0; 0; 0; 0 Participants
Basic Science: Visual Attention in Healthy Participants · Attention
Primary: Gaze Position - Probability of Fixation at Salient Position — .209; .191; .207 Probability
Pain · Back Pain · Low Back Pain
Primary: Ethnic Disparity in Rate of Physician Referral to Physical Therapy — 13; 30; 13; 22 Participants
Hereditary Angioedema
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 70.6; 66.7; 84.6; 62.5 percentage of participants
Cystic Fibrosis
Primary: Cmax — 0.733; 0.595 mg/L
Delirium
Primary: Number of Participants With Delirium — 5 Participants
Abdominal Obesity
Primary: Proportion of Potential Participants Who Are Eligible. — 0.95 Proportion
Multifocal Motor Neuropathy
Primary: Number of Participants With AEs and SAEs — 14; 5; 14; 6 Participants
Acute Graft vs Host Disease · Allogeneic Bone Marrow Transplantation · Adverse Effects
Primary: Number of Participants Who Were Responders (CR, VGPR, or PR) on Day 28 With Low Cumulative Steroid Exposure — 41 Participants
Heart Failure With Reduced Ejection Fraction
Primary: Change in Left Ventricular End-diastolic Dimension (LVEDD) — -1.1; -0.9 centimeters (cm) — p=0.38
RSV Infection
Primary: Number of Participants With Solicited Injection-site Adverse Events (AEs) in RSV Season 1 — 31; 32; 39; 54 Participants
Parkinson Disease
Primary: Changes in the Parkinson's Disease Related Pattern (PDRP) Z-Score From ON Medications to One-week OFF Medications — -0.6 Z score
Endometriosis
Primary: Change From Baseline Cycle in Mean Overall Pelvic Pain Score at Treatment Cycle 3 — -1.8; -1.6; -1.5; -2.0 score on a scale
Hereditary Angioedema
Primary: Number of Participants Experiencing Treatment-emergent Adverse Events — 4; 9; 12 Participants
Inflammation · Oxidative Stress · Smoking
Primary: Carboxyhemoglobin (COHb) in Blood — 3.07; 1.52; 1.49 % of CO saturated hemoglobin — p=<0.001